This early label was criticized and classified as age-associated memory impairment
by Crooks in 1986 (Goldman & Morris, 2001), age-associated cognitive decline (Levy, 1994), and age-related cognitive decline in the DSM IV Criteria (Celsis, 2000), all of which fall within the limits of normal aging.
In 2004, the company completed two phase II safety trials of the drug for age-associated memory impairment
and mild cognitive impairment, with a total of 107 patients.
Pending financing, Accera plans to expand its Phase II trials to look at more Alzheimer's patients over a longer period of time, and a group of patients with age-associated memory impairment
(AAMI), an early precursor to Alzheimer's.
The result of a randomized clinical trial evaluating the efficacy of ginkgo biloba special extract EGb 761 (ginkgo) suggests that ginkgo is not effective as a treatment for older people with dementia or age-associated memory impairment